InspireMD (NSPR)
(Delayed Data from NSDQ)
$2.79 USD
+0.03 (1.09%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $2.79 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NSPR 2.79 +0.03(1.09%)
Will NSPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NSPR
NSPR Stock Declines Despite PMA Application Submission for CGuard
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
Other News for NSPR
InspireMD (NSPR) Receives a Buy from Piper Sandler
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard? Prime Carotid Stent System
InspireMD Advances Stroke Prevention with FDA PMA Submission
InspireMD submits premarket approval application for CGuard Prime system
InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript